Legend Biotech (LEGN) Accounts Payables (2019 - 2025)

Legend Biotech has reported Accounts Payables for 7 years, with the latest figure at $83.0 million in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables rose 115.03% year-over-year to $83.0 million; the trailing twelve-month figure through Dec 2025 stood at $83.0 million (up 115.03% YoY), and the FY2025 full-year result was $83.0 million, up 115.03% from the prior year.
• Accounts Payables for Q4 2025 stood at $83.0 million, down from $102.5 million in the prior quarter.
• The five-year high for Accounts Payables was $102.5 million in Q3 2025, with the low at $7.0 million in Q4 2021.
• Historically, Accounts Payables has averaged $40.8 million across 5 years, with a median of $32.9 million in 2022.
• Annual changes were most pronounced in 2022 — Accounts Payables soared 367.03% — and 2023, when it retreated 6.8%.
• Legend Biotech's Accounts Payables stood at $7.0 million in 2021, then soared by 367.03% to $32.9 million in 2022, then retreated by 6.8% to $30.7 million in 2023, then advanced by 25.92% to $38.6 million in 2024, then soared by 115.03% to $83.0 million in 2025.
• The last three Accounts Payables figures came in at $83.0 million (Q4 2025), $102.5 million (Q3 2025), and $75.4 million (Q2 2025), per Business Quant data.